[SAN ANTONIO, TX – December 1, 2021] A study presented at the Radiological Society of North America (RSNA)’s annual meeting showed Texas-based Seno Medical Instruments, Inc. (Seno)’s Imagio® opto-acoustic ultrasound (OA/US) breast imaging provides significantly better specificity than ultrasound alone. The poster, “Performance of Optoacoustic Ultrasound with an Artificial Intelligence-based Decision Support Tool vs Ultrasound Alone to Classify Benign Versus Malignant Breast Masses: A Pivotal Reader Study,” was presented by Stephen Seiler, MD, Associate Professor, Breast Imaging Division, Department of Radiology at UT Southwestern (Dallas, TX) on November 30.
The study intended to evaluate the gain in specificity using opto-acoustic ultrasound images and an AI-based decision support tool verses ultrasound alone. The study found that OA/US, when used with a decision support tool, has statistically significant better specificity compared to conventional ultrasound alone.
“OA imaging provides different, yet complementary, diagnostic information not provided by conventional ultrasound or its submodalities of Doppler and elastography,” concluded Seiler.
“When used alongside the AI decision support tool, OA imaging has the potential to reduce false positives and thus biopsies of benign masses, versus ultrasound alone, without sacrificing sensitivity.”
Breast biopsy procedures caused by false-positive diagnostic assessments in the United States cost the healthcare system more than $2 billion per year.[i] Seno’s Imagio® technology could mitigate that with its non-invasive OA/US technology to help physicians better differentiate between benign and malignant breast lesions in real time, helping providers characterize and differentiate masses that may—or may not—require more invasive diagnostic evaluation.
Seno’s Chief Executive Officer, Tom Umbel, commented, “The findings by Dr. Seiler and his collaborators further validate the potential for our Imagio® Breast Imaging System to improve patient care by reducing unnecessary biopsy procedures and supporting clinical decision making confidence.”
The company’s OA/US technology combines laser optics and grayscale ultrasound to provide fused functional and anatomical breast imaging. The opto-acoustic images provide a unique blood map in and around breast masses, while the ultrasound provides a traditional anatomical image. Through the appearance or absence of two hallmark indicators of cancer – angiogenesis and deoxygenation – Seno Medical has shown that the Imagio® OA/US Breast Imaging System will be a more effective tool to help radiologists confirm or rule out malignancy compared to traditional diagnostic imaging modalities – without exposing patients to potentially harmful ionizing radiation (x-rays) or contrast agents. In addition to the novel imaging provided by the Imagio® System, Seno includes an artificial intelligence (AI) decision-support tool (the SenoGram®) to aid physicians in interpreting the new images that, along with training and certification, helps radiologists make the transition from ultrasound alone to OA/US imaging.
The system is indicated for use by trained and qualified healthcare providers to evaluate palpable and non-palpable breast abnormalities in adult patients who are referred for diagnostic imaging breast work-up following clinical presentation or other imaging examinations such as screening mammography.
Seno Medical Instruments, Inc. is a San Antonio, Texas-based medical imaging company committed to the development and commercialization of a new modality in cancer diagnosis: opto-acoustic imaging. Approved by the US FDA in January 2021, Seno Medical’s Imagio® Breast Imaging System fuses opto-acoustic technology with ultrasound (OA/US) to generate real-time functional and anatomical images of the breast. To learn more about Seno Medical’s OA/US imaging technology and applications, visit www.SenoMedical.com.
[i] Vlahiotis A, Griffin B, Stavros AT, Margolis J. Analysis of utilization patterns and associated costs of the breast imaging and diagnostic procedures after screening mammography. Clinicoeconomics Outcomes Res 2018;10:157-167.